STAT Plus: Lung cancer drug Lilly bought for $8 billion delivers strong results
The experimental lung cancer drug that led Eli Lilly to spend $8 billion on a smaller biotechnology firm, Loxo Oncology, delivered impressive results Monday in a study being presented at a conference in Barcelona.
A total of 68% of 105 patients — all of whom had been previously failed by chemotherapy — saw a response after taking selpercatinib, previously known as LOXO-292, meaning that their tumors decreased in size by at least 30%. Those responses lasted for a median of 20.3 months, and the patients had progression-free survival of 18.3 months, although those numbers are based on even smaller numbers of patients and could change. The drug is only effective in the 2% of lung cancer patients with a specific gene alteration.
Continue to STAT Plus to read the full story…
